Lantheus Announces Executive Appointments to Accelerate Innovation
15 mai 2024 16h30 HE
|
Lantheus Holdings, Inc.
Jeffrey S. Humphrey, MD appointed Chief Medical Officer;Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”)...
Lantheus Reports First Quarter 2024 Financial Results
02 mai 2024 07h00 HE
|
Lantheus Holdings, Inc.
First Quarter 2024 Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023 GAAP fully diluted net income per share of $1.87, compared to GAAP fully diluted net loss per...
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
18 avr. 2024 08h00 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday,...
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
05 mars 2024 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find,...
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
04 mars 2024 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find,...
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
28 févr. 2024 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
26 févr. 2024 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
22 févr. 2024 07h00 HE
|
Lantheus Holdings, Inc.
Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023GAAP fully...
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
13 févr. 2024 08h30 HE
|
Lantheus Holdings, Inc.
Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ:...
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
08 févr. 2024 08h00 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday,...